Last reviewed · How we verify
Probiotic : Bacillus clausii
At a glance
| Generic name | Probiotic : Bacillus clausii |
|---|---|
| Sponsor | Biocodex |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly (NA)
- Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates (NA)
- Oral-Spray Bacillus Spore Probiotic in Preventing and Supporting Treatment of Dental Caries in Children (NA)
- Microbiota and Probiotic Therapy in Ulcerative Colitis Patients
- Effect of Use of Probiotics on Systemic Infection in Critically Ill Patients: a Double Blind, Randomized, Placebo-controlled Trial (NA)
- Effects of LiveSpo X-SECRET in SupportiveTreatment of Vaginitis (NA)
- Efficacy of Probiotics (LiveSpo Navax) in Preventing Respiratory Diseases in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic : Bacillus clausii CI brief — competitive landscape report
- Probiotic : Bacillus clausii updates RSS · CI watch RSS
- Biocodex portfolio CI